↓ Skip to main content

Dove Medical Press

Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection

Overview of attention for article published in Drug Design, Development and Therapy, September 2020
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (53rd percentile)
  • Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

wikipedia
1 Wikipedia page

Citations

dimensions_citation
8 Dimensions

Readers on

mendeley
20 Mendeley
Title
Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection
Published in
Drug Design, Development and Therapy, September 2020
DOI 10.2147/dddt.s185896
Pubmed ID
Authors

Amanda L Blackmon, Lauren Pinter-Brown

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 20 100%

Demographic breakdown

Readers by professional status Count As %
Other 3 15%
Researcher 2 10%
Student > Ph. D. Student 2 10%
Student > Postgraduate 2 10%
Professor > Associate Professor 1 5%
Other 1 5%
Unknown 9 45%
Readers by discipline Count As %
Medicine and Dentistry 4 20%
Nursing and Health Professions 3 15%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Biochemistry, Genetics and Molecular Biology 1 5%
Mathematics 1 5%
Other 2 10%
Unknown 8 40%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 November 2021.
All research outputs
#8,633,591
of 25,621,213 outputs
Outputs from Drug Design, Development and Therapy
#655
of 2,274 outputs
Outputs of similar age
#178,431
of 426,235 outputs
Outputs of similar age from Drug Design, Development and Therapy
#10
of 40 outputs
Altmetric has tracked 25,621,213 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,274 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 65% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 426,235 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 40 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.